Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,612.00
Bid: 1,611.50
Ask: 1,612.00
Change: -154.50 (-8.75%)
Spread: 0.50 (0.031%)
Open: 1,616.50
High: 1,637.50
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Back to School: "7% downside to European equities"

Thu, 10th Sep 2020 12:21

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni and Stefano
Rebaudo (stefano.rebaudo@thomsonreuters.com) in Milan.

BACK TO SCHOOL: "7% DOWNSIDE TO EUROPEAN EQUITIES" (1110 GMT)

European stocks have risen 38% from March lows and now might be the time to lock in some
profits, at least according to UBS.

"Having been bullish back in March, we now see c.7% downside to European equities,"
strategist at the Swiss bank say.

Their base-case scenario is 340 points for the STOXX 600 at end-2020, based on
expectations earnings are going to fall 33% this year before bouncing 25% in 2021.

Of course things could pan out differently.

* Upside scenario (+13%): multiple expansion continues, positive news on a vaccine, "TINA"
there
is no alternative, US investors return to Europe, a new U.S. fiscal package

* Downside scenario (-20%): rolling regional/national lockdowns, Government support schemes
fade,
U.S. elections, increased US/China trade tensions, a "no deal" Brexit

(Danilo Masoni)

*****

DUNELM'S SPOOKY "SEVERE BUT PLAUSIBLE DOWNSIDE" SCENARIO (1039 GMT)

There's been quite a bit of disappointment to see the shares in British home furnishing
retailer Dunelm retreat this morning despite the encouraging sales achieved in the face
of the coronavirus pandemic.

Much of today's negative price action seems to be blamed on profit taking and on the
decision of Dunelm, a clear lockdown winner, to play it safe and to keep some cash for the
possible rainy days ahead.

"Despite strong current trading, a still uncertain outlook and 'prudent financial approach'
means the Board has chosen not to declare a final dividend for FY20 and management has not
issued FY21 PBT guidance", UBS analysts noted.

But another important part of Dunelm's earnings which might have spooked investors is the
retailer's assessment of what could go wrong.

"There is a fear stalking some companies", commented Neil Wilson at Markets.com, noting the
group's warning of a "severe but plausible" downside scenario which involves lockdowns over
Christmas.

Here's how Dunelm describes in its press release what could happen in a few months to its
business, but by extension to most European retailers:

"The 'severe but plausible downside' scenario is very conservative in assuming a further
national lockdown for ten weeks where our stores are no longer in the 'permitted' status and
where we are unable to offer our Click & Collect service.

We have also assumed that this national lockdown occurs in our peak Christmas and Winter
Sale trading period, with all of the Group's stores being required to shut for ten weeks in the
event of a second Covid-19 outbreak, on top of the downturn in the economy that is already
included in the central case, including potential Brexit-related disruption."

Yikes and merry Xmas everybody!

On a more positive note for Dunelm shareholders, the company "has been a clear relative
winner in the sector through the crisis, with possibly some lasting benefits from strong
customer acquisition," JP Morgan analysts believe.

Anyhow, here's how Dunelm has outperformed the FTSE 250 and how it's comparing with other
top retailers so far in 2020:

(Julien Ponthus)

*****

WHAT ABOUT A PE RATIO OF 100? (0955 GMT)

These days more than ever stock valuations seem to be a matter of how much cash is lying on
the sidelines as central banks are in a "whatever it takes" mood to pour liquidity in order to
avoid the adverse impact of the virus.

Jeroen Blokland, portfolio manager at Robeco, crunched some numbers to measure the
relationship between excess liquidity -- as the difference between money supply and nominal GDP
growth -- and the PE of the S&P 500 stocks.

He concludes that the PE ratio should be at a whooping 100, from around 28 these days.

"Obviously, this is not going to happen, also because nominal GDP growth is expected to
bounce back sharply," he says in a research note. "But it does point out that from a liquidity
perspective, valuation looks far from stretched".

The idea behind this is that if there is more money than needed for economic growth, excess
liquidity will find its way into the stock market.

(Stefano Rebaudo)

*****

BREXIT TURBO-CHARGES UK RISK PREMIA (0850 GMT)

Risk premia on UK assets are rising and will continue to do so as investors fear a messy
divorce with the European Union when Britain finally disentangles at the end of the year.

The European Union could take legal action under its divorce treaty with Britain if today’s
emergency talks do not reassure Brussels sufficiently that a proposed new British law will not
break previously agreed commitments.

An ABN Amro research note recalls that, inside the bond bank index, NatWest Group
over the last seven days staged "the largest underperformance, with their bail-in senior bonds
moving over 30bps wider."

Other names, such as Lloyds and Barclays have only performed a few basis
points better while HSBC, Santander UK and Standard Chartered have suffered a
20 basis points hit.

ABN Amro analysts anticipate that the Brexit negotiations will continue to produce negative
headlines with little achieved in the forthcoming weeks. "UK risks premiums are likely to stay
elevated for the remainder of this year," they say.

The bank index is at 79 basis points (bps) above the swap, roughly 29 bps wider than before
the coronavirus crisis and 158 bps tighter than the pandemic highs experienced in March.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: EUROPE WAVERS BEFORE THE ECB (0725 GMT)

We're off to an uncertain start in Europe this morning with investors awaiting for the ECB
to provide fresh direction with hints of more stimulus to soften the strength of the euro
against the dollar.

Major regional benchmarks were down slightly, following mild initial gains. The STOXX 600 is
last down 0.15%.

Pandemic-hit travel and leisure stocks are up 0.7% with British Airways owner IAG
up over 2% after launching a fully underwritten 2.7 billion euros capital increase to beef up
its balance sheet.

Games Workshop is up an outstanding 18% after saying trading in the three months to
end August topped its expectations.

UK listed housebuilders are doing well after an upbeat RICS survey showed that the
post-lockdown surge in the housing market intensified in August with prices hitting a 4-year
high. Taylor Wimpey and Barratt are both up more than 2%.

Italy's Nexi is up 5% after a report said the payment firms and SIA are close to
clearing a major hurdle to a potential merger.

Weaker oil and basic material stocks weighed. Tech was lower too.

(Danilo Masoni)

*****

ON OUR RADAR: EURO, IAG CAP RISE AND DEALMAKING (0644 GMT)

As we said the European Central Bank's policy meeting and any signals from the central bank
about future easing measures will be the key highlight for investors today.

The euro and bond markets are likely to be most sensitive to ECB news, but we'll be
keeping an eye on stocks too, especially on rate-sensitive sectors like banks.

Besides that, on the corporate front, it doesn't look there is any earth shattering news out
there so far.

This will be the first full session for investors to digest LVMH's decision to
walk away from its planned $16 billion takeover of Tiffany. LVMH was little changed on
the news yesterday.

Airlines, which have been heavily hit by travel restrictions adopted to fight the COVID
pandemic, continue to be under pressure. British Airways owner IAG launched a heavily
discounted 2.7 billion euros capital increase to beef up its finances. The good news here is
that it's fully underwritten.

GlaxoSmithKline said the U.S health regulator approved its lung disease drug Trelegy
Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be
prescribed for uncontrolled asthma in the country.

In M&A, Equinor raised $1.1 billion by selling stakes in offshore wind power
development projects to BP, while in Italy, the government said it's ready to use its
vetting "golden" powers to ensure the Milan exchange is not sold to an unacceptable bidder.

Meanwhile in France, utility Suez reiterated its opposition to Veolia’s
offer for Engie's stake in Suez, saying it undervalued Suez.

Among smaller companies, share placement are expected to put under pressure Ferroamp
, Carasent, and Kojamo.

In earnings news, an upbeat outlook from Akzo Nobel could lift its shares, while Dixons
reported a 56% drop mobile phone in the 17 weeks to end-August.

(Danilo Masoni)

*****

MORNING CALL: IT'S ECB DAY (0530 GMT)

Regardless of whether it's going to have any big impact on markets today the focus is
squarely on the European Central Bank's policy meeting.

The consensus is that rates will remain unchanged although investors expect signals from the
central bank which could possibly weaken the euro.

On the background are still worries over rising Brexit risks and possible further turbulence
in tech stocks, and it may be little surprise that following yesterday's rebound in Europe and
the U.S., futures are giving mixed signals at the moment.

The Euro STOXX 500 futures are up 0.3%, FTSE 100 futures are down 0.3% and Wall Street
futures are moving flat to slightly higher.

(Danilo Masoni)

*****

More News
13 Aug 2023 14:06

Sunday newspaper round-up: White Hydrogen, Bank of England, AI

(Sharecast News) - America's Geological survey estimates that if even a small fraction of naturally occurring - and clean or so-called 'white' - hydrogen beneath the earth's surface were recovered, that would last for hundreds of years. Among the backers of the hydrogen industry is Bill Gates, who ploughed $90m into Koloma, a company hunting for natural hydrogen along the US's Midcontinental Rift System. White hydrogen has also been discovered in Europe, in France's Lorraine region. Nonetheless, the true potential of the stuff will hinge on the findings from those early projects, says Philip Ball, research fellow at Keele University. - Guardian

Read more
10 Aug 2023 15:46

UK dividends calendar - next 7 days

Friday 11 August 
Blackrock Latin American Investment Trust PLCdividend payment date
Caffyns PLCdividend payment date
CMC Markets PLCdividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Next 15 Group PLCdividend payment date
Ninety One PLC and Ltddividend payment date
Schroder European Real Estate Investment Trust PLCdividend payment date
Sportech PLCspecial dividend payment date
Telecom Plus PLCdividend payment date
Triad Group PLCdividend payment date
Wincanton PLCdividend payment date
Monday 14 August 
Mountview Estates PLCdividend payment date
Tuesday 15 August 
Tatton Asset Management PLCdividend payment date
Wednesday 16 August 
Murray International Trust PLCdividend payment date
Shoe Zone PLCdividend payment date
Thursday 17 August 
4imprint Group PLCex-dividend payment date
abrdn PLCex-dividend payment date
abrdn Property Income Trust Ltdex-dividend payment date
Anglo American PLCex-dividend payment date
Baillie Gifford UK Growth Trust PLCex-dividend payment date
Berkeley Group Holdings PLCex-dividend payment date
BlackRock Sustainable American Income Trust PLCex-dividend payment date
Bridgepoint Group PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
ConvaTec Group PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
GSK PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
Hiscox Ltdex-dividend payment date
Impact Healthcare REIT PLCex-dividend payment date
Imperial Brands PLCex-dividend payment date
Investec PLC and Ltdex-dividend payment date
iomart Group PLCex-dividend payment date
Keller Group PLCex-dividend payment date
Lancashire Holdings Ltdex-dividend payment date
London Stock Exchange Group PLCex-dividend payment date
Montanaro European Smaller Cos Trust PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Rotork PLCex-dividend payment date
Sabre Insurance Group PLCex-dividend payment date
Schroders PLCex-dividend payment date
Sirius Real Estate Ltddividend payment date
Tritax EuroBox PLCex-dividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
7 Aug 2023 08:12

PRESS: Inflexion among firms looking to buy Haleon's nicotine business

(Alliance News) - Sky News reported on Sunday that Inflexion Private Equity Partners is among suitors for Haleon PLC's Nicotinell anti-smoking aid.

Read more
3 Aug 2023 16:31

GSK Nigeria calls an end to its business, to return cash

ABUJA, Aug 3 (Reuters) - GlaxoSmithKline (GSK) Nigeria said on Thursday it plans to stop doing business after evaluating the options for moving to a third-party distribution model for its drugs and consumer healthcare goods.

Read more
2 Aug 2023 20:45

TOP NEWS: GSK sues Pfizer over patent infingements for RSV vaccine

(Alliance News) - GSK PLC on Wednesday sued Pfizer Inc over patent infringement, alleging Pfizer's respiratory syncytial virus vaccine steals key elements of GSK's version.

Read more
2 Aug 2023 15:14

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in a U.S. court on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 14:28

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 10:41

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

Read more
2 Aug 2023 08:23

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

Read more
31 Jul 2023 19:42

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

Read more
31 Jul 2023 12:21

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

Read more
31 Jul 2023 09:16

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
26 Jul 2023 11:06

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*

Read more
26 Jul 2023 09:28

TOP NEWS: GSK raises annual guidance on quarterly earnings growth

(Alliance News) - GSK PLC on Wednesday upgraded its full-year guidance, after seeing a strong quarterly performance on the strength of segments like HIV and Vaccines.

Read more
26 Jul 2023 07:55

GSK lifts full-year guidance after 'excellent' Q2

(Sharecast News) - GSK lifted its full-year guidance on Wednesday after an "excellent" second quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.